Crizanlizumab plus standard of care versus standard of care for sickle cell nephropathy

Phase 2, randomised, open-label trial in sickle cell disease (SCD), chronic kidney disease (CKD) and sickle cell nephropathy (SCN) comparing Crizanlizumab + standard of care with Standard of care alone (2 arms). Primary endpoint: Proportion of patients with at least 30% decrease in ACR at 12 months compared to baseline. Started Sep 2020; status: active, not recruiting.